
I-Mab IMAB
Quarterly report 2025-Q2
added 03-21-2026
I-Mab Operating Cycle 2011-2026 | IMAB
Annual Operating Cycle I-Mab
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 271 | 15.5 | 4.65 | - | - | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 271 | 4.65 | 96.9 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M | ||
|
Albireo Pharma
ALBO
|
40.8 | - | -0.23 % | $ 916 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
Altimmune
ALT
|
7.85 K | $ 3.44 | 2.99 % | $ 303 M | ||
|
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | ||
|
Amgen
AMGN
|
282 | $ 349.77 | 0.57 % | $ 188 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
237 | $ 19.23 | -1.38 % | $ 899 M | ||
|
Amarin Corporation plc
AMRN
|
213 | $ 14.6 | 0.76 % | $ 6.06 B | ||
|
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
394 | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | ||
|
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | ||
|
ChemoCentryx
CCXI
|
3.1 | - | - | $ 3.74 B | ||
|
Aytu BioScience
AYTU
|
360 | $ 2.63 | 0.77 % | $ 16.5 M | ||
|
BioDelivery Sciences International
BDSI
|
436 | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B | ||
|
Benitec Biopharma
BNTC
|
141 | $ 11.19 | 1.91 % | $ 461 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
50 | $ 4.42 | 4.25 % | $ 734 M | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
Brickell Biotech
BBI
|
254 | - | -5.38 % | $ 6.06 M | ||
|
Calithera Biosciences
CALA
|
28.8 | - | -10.95 % | $ 876 K | ||
|
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | ||
|
Cara Therapeutics
CARA
|
52.4 | - | -3.03 % | $ 260 M |